Hematology

First gene therapy approved for severe hemophilia A

In phase III study, recombinant VWF not superior to cheaper alternative for type 1 and 2 cases

Study suggests "watch and wait" should remain standard of care

Health news and commentary from around the Web gathered by MedPage Today staff

Approval of glofitamab was based on a phase I/II study that showed a 56% overall response rate

One young patient achieved molecular remission within 28 days of infusion

Patients with depression alone had the worst overall survival

Results "indicate that exa-cel can provide a one-time functional cure," says researcher

All patients had progressed on BTK inhibitors and most had failed venetoclax

Findings could pave the way for considering common complication in stewardship programs

PET-negative patients after chemoimmunotherapy fared well with observation alone

The CAR T-cell therapy led to significantly longer overall survival

High rates of deep, durable response with bispecific antibody, rapidly produced CAR T-cell agents

Condition may exacerbate racial disparities in severe maternal morbidity